

Supplemental table 1. Patient characteristics

<i>Clinical history</i>	Mean/*Median	Inter-quartile range
	N	%
Ethnicity		
Caucasian	47	87
Non-caucasian	7	13
5-α reductase inhibitor use	9	17
<i>Biopsy history</i>	N	%
Initial biopsy	16	30
Prior biopsy	38	70
Prior negative biopsy	15	28
Prior positive biopsy	23	43
3+3	20	37
3+4	3	6
<i>MRI regions of interest</i>	N	CaP positive (%)
Overall MRI suspicion		
2	16	5 (31)
3	40	21 (53)
4	29	20 (69)
5	16	12 (75)
Total	101	58 (57)
<i>Fusion biopsy</i>	Cores, mean	Cores, CaP positive (%)
Mapping biopsy	12	2.4 (20)
Targeted biopsy	5.9	2.5 (42)
Total cores	18	4.9 (28)
<i>Histopathology</i>	N	%
Number of CaP foci (mean)	2.1	—
pT stage		
T2a	11	20
T2b	4	7
T2c	18	33
T3a	15	28
T3b	5	9
T4	1	2
N stage		
Nx	13	24
N0	39	72
N1	2	4

CaP, cancer

Supplemental table 2. Determinants of Gleason score, N (%)

Gleason score	Mapping biopsy	Targeted biopsy	Combined	Whole-mount
No cancer	9 (17)	10 (19)	—	—
3+3	9 (17)	9 (17)	4 (7)	2 (4)
3+3+4	—	—	—	5 (9)
3+4	22 (41)	20 (37)	27 (50)	23 (43)
3+5	1 (2)	0 (0)	1 (2)	0 (0)
4+3	6 (11)	7 (13)	10 (19)	4 (7)
4+3+5	—	—	—	11 (20)
4+4	3 (6)	1 (2)	2 (4)	3 (5)
4+4+5	—	—	—	1 (2)
4+5	3 (6)	6 (11)	9 (17)	4 (7)
5+4	1 (2)	1 (2)	1 (2)	1 (2)
Total	54 (100)	54 (100)	54 (100)	54 (100)

Cross tabulation of fusion biopsy and whole-mount pathology Gleason score, N

Combined fusion biopsy							
Whole-mount	3+3	3+4	3+5	4+3	4+4	4+5	5+4
3+3	2	0	0	0	0	0	0
3+3+4	1	4	0	0	0	0	0
3+4	1	18	0	4	0	0	0
4+3	0	3	0	0	0	1	0
4+3+5	0	1	1	4	1	4	0
4+4	0	0	0	2	1	0	0
4+4+5	0	1	0	0	0	0	0
4+5	0	0	0	0	0	4	0
5+4	0	0	0	0	0	0	1

Biopsy results are provided by modality, with the higher grade of either mapping or targeted biopsy considered the combined fusion biopsy result. No tertiary patterns are assigned at biopsy. Whole-mount radical prostatectomy specimens are scored according to pattern prevalence, including a tertiary pattern if present.